高级检索
当前位置: 首页 > 详情页

CC Chemokine Ligand 18 Promotes Cell Proliferation and Metastasis of Urothelial Carcinoma via Activating PI3K/mTOR Signaling in Patient with Renal Transplantation

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [2]Department of Urology, Beijing Luhe Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: CC chemokine ligand 18 PI3K-mTOR signaling Urothelial carcinoma Renal transplantation

摘要:
Objective: The study aimed to investigate the role of chemokine (C-C motif) ligand 18 (CCL18) in the progression of urothelial carcinoma (UC) after renal transplants (RT). Methods: Tissues were collected from 60 patients with UC in which 24 were after RT. The tissues were all obtained from patients after radical cystectomy. Expression levels of CCL18 were examined by immunohistochemistry, RT-polymerase chain reaction (RT-PCR), and quantitative RT-PCR, respectively. WST-1 assay was performed to determine proliferative capacity of UC cells. Migration and invasion of UC cells were analyzed by the using of chemotaxis and Transwell system. Western blotting was applied to assess the activation of PI3K-mTOR (Mammalian Target of Rapamycin) signaling. Results: Compared to normal urothelial tissues, the expression levels of CCL18 were significantly increased in tumors of UC, and even more in tumors of UC after RT. Ectopic expression of CCL18 efficiently enhanced the proliferation of UC cells and moreover, exacerbated the migration and invasion of UC cells. Furthermore, overexpressed CCL18 increased the phosphorylation of PI3K, Akt, and mTOR in UC cells, suggesting the hyperactivation of PI3K/Akt/mTOR signaling. Conclusions: The results demonstrate the critical role of CCL18 in the progression of UC, especially in receipt with RT. Our study indicates that CCL18 could serve as a biomarker and therapeutic target in diagnosis of recipients with UC after RT. (c) 2018 S. Karger AG, Basel

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
JCR分区:
出版当年[2016]版:
Q3 UROLOGY & NEPHROLOGY
最新[2023]版:
Q3 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2016版] 出版当年五年平均[2012-2016] 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者单位: [1]Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [2]Department of Urology, Beijing Luhe Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构: [1]Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [*1]Department of Urology, Beijing Friendship Hospital Capital Medical University, 95 Yongan Road Beijing 100050 (China)
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)